KPP Advisory Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$367K Sell
15,236
-2,368
-13% -$61.9K 0.05% 272
2026
Q1
$494K Buy
17,604
+52
+0.3% +$1.38K 0.07% 218
2025
Q4
$437K Sell
17,552
-259
-1% -$6.53K 0.06% 215
2025
Q3
$454K Buy
17,811
+142
+0.8% +$3.5K 0.07% 215
2025
Q2
$428K Buy
17,669
+9,343
+112% +$218K 0.07% 209
2025
Q1
$211K Sell
8,326
-906
-10% -$23.7K 0.04% 276
2024
Q4
$245K Buy
9,232
+594
+7% +$16.1K 0.06% 221
2024
Q3
$250K Sell
8,638
-155
-2% -$4.52K 0.06% 217
2024
Q2
$246K Sell
8,793
-193
-2% -$5.31K 0.07% 209
2024
Q1
$249K Sell
8,986
-4,725
-34% -$131K 0.07% 206
2023
Q4
$395K Sell
13,711
-9,642
-41% -$291K 0.35% 74
2023
Q3
$775K Buy
+23,353
New +$826K 0.26% 77

Other funds holding PFE

KPP Advisory Services's PFE Position: Q2 2026 in Review

KPP Advisory Services reduced its Pfizer (PFE) stake by 13% in Q2 2026, selling an estimated $61.9K and leaving 15,236 shares worth $367K. The position accounts for 0.05% of the portfolio, ranked #272.

KPP Advisory Services first reported a position in PFE in Q3 2023 and has held it in 12 quarters since. The position peaked at $775K in Q3 2023. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • KPP Advisory Services held 15,236 shares of Pfizer worth $367K as of Q2 2026.
  • KPP Advisory Services sold 2,368 Pfizer shares in Q2 2026, an estimated $61.9K.
  • Pfizer made up 0.05% of KPP Advisory Services's portfolio in Q2 2026, its #272 holding.
  • KPP Advisory Services first reported a position in Pfizer in Q3 2023 and has held it in 12 quarters since.
  • KPP Advisory Services's Pfizer position peaked at $775K in Q3 2023.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on KPP Advisory Services's 13F filing for Q2 2026, filed 24 Jul 2026.